Pulmonx (NASDAQ:LUNG) Issues Earnings Results

Pulmonx (NASDAQ:LUNG) issued its earnings results on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12, Zacks reports. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. Pulmonx updated its FY 2025 guidance to EPS.

Pulmonx Stock Down 5.0 %

Shares of NASDAQ:LUNG opened at $6.64 on Thursday. The firm’s 50 day simple moving average is $6.42 and its 200 day simple moving average is $6.74. Pulmonx has a fifty-two week low of $5.46 and a fifty-two week high of $14.60. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Insider Activity at Pulmonx

In other news, General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.19, for a total transaction of $34,026.43. Following the transaction, the general counsel now owns 197,851 shares in the company, valued at $1,224,697.69. The trade was a 2.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the transaction, the director now owns 1,071,974 shares of the company’s stock, valued at $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,199 shares of company stock worth $208,859. 5.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

LUNG has been the topic of several recent analyst reports. Wells Fargo & Company reduced their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus decreased their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Finally, Citigroup reaffirmed a “neutral” rating and issued a $7.50 price target (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.